Print
Inherited gene mutations found in pancreatic cancer families in Spain
https://www.facingourrisk.org/XRAY/genetic-testing-important-for-people-with-family-history-of-pancreatic-cancer
Full article: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(20)30050-5/fulltext
This study looked for inherited mutations in genes known to be linked to hereditary pancreatic cancer. The results provide additional evidence that most hereditary pancreatic cancer is due to inherited mutations in genes that were previously associated with other forms of cancer. (10/29/20)
Questions To Ask Your Health Care Provider
- Do I meet criteria for genetic counseling and testing for high-risk genes linked to pancreatic cancer?
- What genetic tests should I have?
- Can you refer me to a genetic counselor?
- What are the benefits and risks of genetic testing?
- What do my genetic test results mean?
- Can you provide a copy of my genetic test results?
- How will genetic testing affect my medical options?
Open Clinical Trials
The following studies are looking at risk management for pancreatic cancer:
Other clinical trials for pancreatic cancer screening and prevention may be found here.
The following treatment studies are enrolling people diagnosed with pancreatic cancer.
- NCT04548752: Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation. This study researches whether adding the drug pembrolizumab to the PARP inhibitor olaparib works better than olaparib alone for treating metastatic pancreatic cancer in people with an inherited BRCA1 or BRCA2 mutation.
- NCT05252390: NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors. This study tests the safe and effectiveness of the experimental drug NUV-868 alone and in combination with a PARP inhibitor in people with different types of advanced cancers.
- NCT04493060: Treating Metastatic Pancreatic Cancer with an Inherited or Tumor BRCA1/2 or PALB2 Mutation with Niraparib and Dostarlimab. This study looks at how well the PARP inhibitor niraparib and the immunotherapy drug dostarlimab work together for treating patients with metastatic pancreatic cancer and an inherited or tumor mutation in BRCA1, BRCA2, PALB2, BARD1, RAD51C or RAD51D.
- NCT04150042: SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells. This study looks at whether melphalan, BCNU, vitamin B12b and vitamin C followed by autologous (self) bone marrow stem cell infusion is safe and effective for treating patients with advanced pancreatic cancer or stage 4, HER2-negative breast cancer for people with a BRCA1, BRCA2 or PALB2 inherited mutation.
- NCT04666740: Pembrolizumab and Olaparib for Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy. This study compares the combination of the immunotherapy pembrolizumab and the PARP inhibitor olaparib to olaparib alone. It enrolls metastatic pancreatic cancer with an HRD-positive tumor test or disease that has responded well to first-line or second-line platinum therapy.
- NCT04858334: Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (APOLLO). This study compares the usual approach (observation) to treatment for one year with olaparib in patients with a BRCA1, BRCA2 or PALB2 mutation.
- NCT04550494: Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib. This study looks at the safety and effectivenss of the drug talazoparib for treating people with advanced breast, gastric, ovarian, pancreatic or other cancers with an inherited mutation or an acquired mutation in certain DNA repair genes, such as BRCA1, BRCA2, ATM, CHEK2, PALB2 and others.
The following vaccine studies are enrolling people with pancreatic cancer.
- NCT05111353: Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery. This study looks at the safety of an neoantigen vaccines for pancreatic cancer patients following neoadjuvant chemotherapy. Participants receive either the vaccine following by neoadjuvant chemotherapy and surgery or the vaccine after neoadjuvant chemotherapy and before surgery.
Other clinical trials for people with pancreatic cancer can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.